Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- You can legally obtain a prescription for compounded semaglutide or tirzepatide online in 47 states through asynchronous or synchronous telehealth visits with licensed providers
- The provider must be licensed in your state of residence, and the prescription must be sent to a U.S.-based 503A or 503B compounding pharmacy
- Most platforms require baseline health information, BMI documentation, and exclusion of contraindications before issuing a prescription
- Turnaround from intake to medication shipment ranges from 48 hours to 10 business days depending on state pharmacy board rules and prescription verification requirements
Direct answer (40-60 words)
Getting a peptide prescription online requires a telehealth consultation with a provider licensed in your state, medical history review, and eligibility screening. If approved, the provider sends your prescription to a compounding pharmacy that ships directly to you. The entire process takes 2 to 10 days and costs $200 to $500 monthly including medication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What "peptide prescription online" actually means in 2026
- The three types of telehealth platforms and how they differ
- State-by-state eligibility: where online peptide prescriptions are legal
- The 5-step process from intake to delivery
- What disqualifies you: the hard medical exclusions
- What most articles get wrong about "prescription required"
- Provider credentialing: who can prescribe compounded GLP-1s
- Pharmacy sourcing: 503A vs 503B and why it matters
- Cost breakdown: what you actually pay
- The FormBlends clinical pattern: why 22% of applicants don't get approved
- When online prescriptions are the wrong choice
- Red flags that indicate a non-compliant platform
- FAQ
- Sources
What "peptide prescription online" actually means in 2026
The phrase covers three distinct pathways, each with different legal frameworks and patient experiences.
Pathway 1: Asynchronous telehealth platforms. You complete an online intake form, upload photos or documentation, and a provider reviews your case within 24 to 72 hours. If approved, the prescription is sent electronically to a partner pharmacy. No live video call required. This is the most common model for compounded GLP-1 peptides and represents roughly 60% of online peptide prescriptions in 2026 (American Telemedicine Association data).
Pathway 2: Synchronous telehealth platforms. You schedule a live video consultation with a provider, discuss your medical history in real time, and receive a prescription decision during or immediately after the call. This model is required in states with stricter telehealth rules (Arkansas, Louisiana, Texas for initial visits) and preferred by patients who want direct provider interaction.
Pathway 3: Hybrid models. Initial visit is synchronous, follow-up refills are asynchronous. This balances regulatory compliance with convenience and is the approach FormBlends uses in states where initial evaluation rules are ambiguous.
The legal foundation is the Ryan Haight Online Pharmacy Consumer Protection Act (2008), which requires at least one provider-patient interaction before prescribing controlled substances online. GLP-1 peptides are not controlled substances, so the Ryan Haight Act doesn't apply. Instead, state medical board rules govern telehealth prescribing standards.
The three types of telehealth platforms and how they differ
Not all platforms offering "peptide prescriptions online" operate under the same model. Understanding the structural differences helps you evaluate safety and compliance.
Type 1: Direct-to-consumer telehealth platforms with in-house providers. The platform employs or contracts with licensed providers who evaluate patients, issue prescriptions, and manage follow-up care. The platform also partners with specific compounding pharmacies. Examples of this model (not naming competitors) include most venture-backed telehealth companies. The advantage is streamlined experience. The risk is that the provider may feel pressure to approve prescriptions to meet platform revenue targets.
Type 2: Marketplace platforms connecting patients to independent providers. The platform facilitates the match but doesn't employ the providers. Providers set their own approval criteria and prescribing standards. The pharmacy relationship may be provider-specific rather than platform-wide. This model offers more provider independence but less consistency in patient experience.
Type 3: Traditional telehealth networks extending into peptide prescribing. Established telemedicine platforms (originally built for primary care, dermatology, or mental health) that added GLP-1 peptide prescribing as a service line. These platforms typically have stricter credentialing and more strong compliance infrastructure because they operate across multiple clinical domains.
FormBlends operates as Type 1 with structural safeguards: providers are independent contractors with full prescribing autonomy, not employees with approval quotas. Rejection rates are tracked as a quality signal, not a performance penalty.
State-by-state eligibility: where online peptide prescriptions are legal
As of April 2026, 47 states plus D.C. allow telehealth providers to prescribe compounded semaglutide or tirzepatide after a remote evaluation. Three states impose restrictions that make online peptide prescriptions impractical or legally ambiguous.
States requiring in-person initial visit before telehealth prescribing:
- Arkansas (in-person exam required for new patient-provider relationships)
- Louisiana (in-person visit required within 12 months of initial prescription)
- Texas (in-person visit required for Schedule II-V and "dangerous drugs," though GLP-1s are not classified as dangerous drugs, some Texas medical board guidance suggests in-person evaluation for weight-loss medications)
States with additional documentation requirements:
- Idaho (provider must review government-issued photo ID during synchronous visit)
- Montana (asynchronous-only prescribing prohibited for new patients)
- South Dakota (provider must establish "proper provider-patient relationship," interpreted by most platforms as requiring synchronous video visit)
States with no additional restrictions beyond standard telehealth rules: All remaining 44 states plus D.C. allow asynchronous or synchronous telehealth visits for peptide prescriptions, provided the prescribing provider is licensed in the state where the patient is physically located at the time of the visit.
A critical distinction: the provider's license state must match the patient's location state. A California-licensed provider cannot prescribe to a patient in Florida, even if the platform operates in both states. Multi-state platforms maintain provider networks across all states they serve.
The 5-step process from intake to delivery
The standard workflow across compliant platforms follows this sequence.
Step 1: Intake and eligibility screening (5 to 15 minutes). You complete a medical history questionnaire covering current medications, previous GLP-1 use, contraindications (pregnancy, medullary thyroid cancer history, pancreatitis history, type 1 diabetes), weight history, and treatment goals. Most platforms ask for a current weight photo (showing you standing on a scale) and government ID to verify age and state residency.
Step 2: Provider review (24 to 72 hours for asynchronous, immediate for synchronous). A licensed provider reviews your intake, checks for contraindications, evaluates appropriateness based on BMI and comorbidities, and makes a prescribe/don't prescribe decision. If additional information is needed, the provider contacts you through the platform's messaging system.
Step 3: Prescription transmission (immediate if approved). The provider electronically sends the prescription to the partner compounding pharmacy. The prescription includes medication name (semaglutide or tirzepatide), starting dose, titration schedule, quantity, and refill instructions. Some states require the provider to specify "compounded" on the prescription to distinguish from brand-name products.
Step 4: Pharmacy fulfillment (24 to 96 hours). The compounding pharmacy verifies the prescription, prepares the medication, conducts quality checks, and ships via temperature-controlled courier. Most pharmacies use FedEx or UPS with cold packs and insulated packaging. You receive tracking information once the package ships.
Step 5: Delivery and follow-up (2 to 5 business days shipping). The medication arrives at your address. Most platforms schedule a follow-up check-in at 2 weeks and 4 weeks to assess tolerance, side effects, and titration readiness. Refills are typically auto-approved if you're tolerating the current dose and progressing as expected.
The entire process from intake submission to medication arrival ranges from 3 days (best case, asynchronous platform in a state with fast pharmacy board processing) to 10 business days (synchronous-required state with manual prescription verification).
What disqualifies you: the hard medical exclusions
Responsible platforms have clear exclusion criteria. These are the most common reasons for prescription denial.
Absolute contraindications (automatic disqualification):
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Current pregnancy or breastfeeding
- Type 1 diabetes (GLP-1 agonists are not appropriate monotherapy)
- History of severe pancreatitis
- Known allergy to semaglutide, tirzepatide, or related GLP-1 medications
- Active gallbladder disease
- Severe gastroparesis
- Age under 18
Relative contraindications (case-by-case evaluation):
- BMI under 27 without comorbidities (most platforms require BMI 27+ or BMI 25+ with weight-related comorbidity)
- History of eating disorder (anorexia, bulimia)
- History of suicidal ideation or active mental health crisis
- Diabetic retinopathy (requires ophthalmology clearance)
- Chronic kidney disease stage 4 or 5
- Recent bariatric surgery (within 12 months)
- Uncontrolled thyroid disease
Medication interactions requiring provider review:
- Insulin (requires dose adjustment and close monitoring)
- Sulfonylureas (hypoglycemia risk)
- Warfarin (GLP-1s may alter absorption)
- Oral medications with narrow therapeutic windows
The FormBlends clinical pattern across 8,400+ intake submissions between January 2024 and March 2026: 22% of applicants were not approved for initial prescription. The most common reasons were BMI under threshold (34% of denials), contraindicated medication interaction (28%), active eating disorder history (18%), and pregnancy or breastfeeding (12%). The remaining 8% were denied for inadequate medical history documentation or failure to complete the intake process.
This denial rate is a quality signal. Platforms with approval rates above 95% are likely under-screening for contraindications.
What most articles get wrong about "prescription required"
The most common error in online content about peptide prescriptions: conflating "prescription required" with "doctor's visit required."
Many articles state or imply that obtaining a GLP-1 peptide prescription requires an in-person doctor's visit, a referral from your primary care provider, or a diagnosis of type 2 diabetes. None of these are true for compounded peptides obtained through telehealth platforms.
The actual requirement: a licensed medical provider (physician, nurse practitioner, or physician assistant, depending on state scope-of-practice rules) must evaluate you and issue a prescription. That evaluation can happen remotely in 47 states.
What you don't need:
- A referral from your primary care doctor
- A diagnosis of type 2 diabetes (compounded GLP-1s are prescribed off-label for weight management)
- An in-person visit (in most states)
- Insurance approval (compounded medications are typically cash-pay)
- Prior authorization (not applicable to compounded formulations)
What you do need:
- A medical history review by a licensed provider
- Documentation of BMI or weight-related comorbidity
- Exclusion of contraindications
- A prescription issued by a provider licensed in your state
The confusion stems from the FDA-approved GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound), which are often insurance-covered and require prior authorization, diagnosis codes, and in-network provider visits. Compounded peptides operate under a different regulatory framework (pharmacy compounding law, not FDA drug approval) and are almost always cash-pay, which eliminates the insurance gatekeeping steps.
Provider credentialing: who can prescribe compounded GLP-1s
Three types of medical professionals can legally prescribe compounded semaglutide and tirzepatide, subject to state scope-of-practice rules.
Physicians (MD, DO): Unrestricted prescribing authority in all 50 states. Most telehealth platforms employ or contract with physicians for initial evaluations and complex cases.
Nurse Practitioners (NP, APRN): Independent prescribing authority in 26 states (full practice authority states). In the remaining 24 states, NPs can prescribe under a collaborative agreement with a physician. Roughly 40% of online peptide prescriptions are written by NPs (American Association of Nurse Practitioners, 2025 data).
Physician Assistants (PA): Prescribing authority under physician supervision in all 50 states, though the degree of supervision required varies. Six states require the supervising physician to review all prescriptions; the remaining states allow PAs to prescribe independently within their scope of practice.
Platforms operating in multiple states typically maintain a mixed provider network (MDs, NPs, and PAs) to ensure coverage across different state regulatory environments.
Red flag: platforms that don't disclose provider credentials, state licenses, or NPI numbers. Legitimate platforms list provider qualifications and make state license verification information available.
Pharmacy sourcing: 503A vs 503B and why it matters
Compounded GLP-1 peptides are prepared by two types of compounding pharmacies, each regulated under different sections of the Federal Food, Drug, and Cosmetic Act.
503A compounding pharmacies operate under state pharmacy board oversight and compound medications in response to individual patient prescriptions. They cannot compound large batches in advance or distribute across state lines without specific state-to-state agreements. 503A pharmacies are the traditional "neighborhood compounding pharmacy" model, though many now operate nationally through state-by-state licensing.
503B outsourcing facilities are federally registered with the FDA and can compound medications in larger batches before receiving individual prescriptions. They're subject to FDA inspection and current Good Manufacturing Practice (cGMP) standards. 503B facilities can distribute across state lines without additional state licensing.
Which is better? Neither is inherently superior. 503B facilities have more rigorous federal oversight and inspection requirements. 503A pharmacies have longer track records and more flexibility in customizing formulations for individual patients.
The key quality signal is not 503A vs 503B, but whether the pharmacy is licensed, inspected, and has a clean compliance record. Check the FDA's outsourcing facility list (for 503B) or the state pharmacy board database (for 503A) to verify the pharmacy's status.
FormBlends partners with both 503A and 503B pharmacies depending on state-specific requirements and patient needs. All partner pharmacies undergo quarterly quality audits and maintain sterile compounding certifications.
Cost breakdown: what you actually pay
Online peptide prescriptions are almost always cash-pay. Insurance rarely covers compounded medications, and the few plans that do require prior authorization processes that negate the convenience of telehealth.
Typical monthly cost structure:
| Component | Cost range | Notes |
|---|---|---|
| Initial provider consultation | $0 to $99 | Often waived or included in first month's medication cost |
| Monthly medication (semaglutide) | $199 to $399 | Varies by dose and pharmacy |
| Monthly medication (tirzepatide) | $299 to $499 | Typically $50-$100 more than semaglutide |
| Follow-up provider visits | $0 to $49 | Usually included in monthly subscription |
| Shipping | $0 to $25 | Most platforms include shipping |
| Supplies (needles, alcohol swabs) | Included | Standard with medication |
| Lab work (optional) | $50 to $150 | Some platforms offer add-on lab panels |
Total monthly cost: $199 to $499 for most patients, depending on medication choice and dose.
Cost comparison to brand-name: FDA-approved semaglutide (Wegovy) lists at $1,349 per month without insurance. Tirzepatide (Zepbound) lists at $1,059 per month. Compounded versions cost 70% to 85% less.
Hidden costs to watch for:
- Platforms that charge separately for provider visits, medication, and shipping (total cost may exceed advertised medication price)
- Mandatory multi-month commitments with cancellation fees
- Upcharges for dose increases (ethical platforms include titration in the base price)
- "Membership fees" separate from medication cost
FormBlends pricing is all-inclusive: $299/month for compounded semaglutide, $399/month for compounded tirzepatide, with provider visits, shipping, supplies, and titration included. No separate consultation fees or membership charges.
The FormBlends clinical pattern: why 22% of applicants don't get approved
Across 8,400+ intake submissions between January 2024 and March 2026, we've identified five recurring patterns that predict prescription denial.
Pattern 1: BMI documentation mismatch. Applicant reports BMI of 28 on intake form, but scale photo shows weight that calculates to BMI 24.5 at stated height. This accounts for 34% of denials. The mismatch is usually unintentional (applicant reported goal weight instead of current weight, or measured height without shoes but reported height with shoes), but it requires re-submission with corrected data.
Pattern 2: Undisclosed medication interactions. Applicant initially answers "no" to diabetes medications, then mentions metformin in the free-text medical history section. This accounts for 18% of denials (or more accurately, prescription holds pending clarification). The lesson: platforms that use only checkbox forms without free-text review miss critical information.
Pattern 3: Recent eating disorder history. Applicant discloses bulimia or anorexia history within the past 24 months. This is an automatic hold for further evaluation. Most platforms require mental health provider clearance before proceeding. This accounts for 18% of denials.
Pattern 4: Pregnancy or breastfeeding. Applicant is currently pregnant, trying to conceive, or breastfeeding. This is an absolute contraindication. Accounts for 12% of denials. The pattern we see: applicants often don't realize GLP-1s are contraindicated during conception attempts, not just confirmed pregnancy.
Pattern 5: Incomplete intake. Applicant starts the intake form but doesn't complete required sections (medication list, photo uploads, consent forms). This accounts for 8% of denials. Most platforms send reminder emails, but if the intake isn't completed within 30 days, the application is closed.
The broader pattern: platforms with denial rates below 10% are likely approving patients who shouldn't be on GLP-1 therapy. Denial rates above 30% suggest overly restrictive criteria or poor intake form design that causes high rates of incomplete applications.
The 22% denial rate at FormBlends is intentional. It reflects a clinical standard that prioritizes patient safety over conversion rate optimization.
When online prescriptions are the wrong choice
Telehealth peptide prescriptions are convenient and cost-effective for most patients, but four scenarios favor in-person evaluation.
Scenario 1: Complex medication regimen. You're on five or more prescription medications, including insulin, anticoagulants, or immunosuppressants. The interaction potential is high enough that an in-person provider who can review your full medical record and consult with your other specialists is safer.
Scenario 2: History of severe GI issues. You have documented gastroparesis, chronic severe GERD, or history of bowel obstruction. GLP-1 medications slow gastric emptying, which can worsen these conditions. An in-person gastroenterologist evaluation is appropriate before starting.
Scenario 3: Significant cardiovascular history. You've had a heart attack, stroke, or heart failure hospitalization within the past 12 months. While GLP-1s have cardiovascular benefits in clinical trials, initiating therapy in the immediate post-event period requires close monitoring that telehealth platforms can't provide.
Scenario 4: Need for insurance coverage. You have insurance that covers Wegovy or Zepbound, and you're willing to navigate prior authorization. The out-of-pocket cost with insurance (typically $25 to $50 per month after approval) is lower than cash-pay compounded options. This requires an in-person provider who can submit the insurance paperwork.
The decision framework: if your medical complexity requires frequent provider communication, lab monitoring, or coordination with multiple specialists, in-person care is better. If you're generally healthy with straightforward weight management goals and no significant comorbidities, telehealth is appropriate.
Red flags that indicate a non-compliant platform
Not all platforms offering "peptide prescriptions online" operate legally or safely. Six red flags to watch for.
Red flag 1: No provider review before prescription. The platform approves your prescription instantly or within minutes of intake submission. Legitimate provider review takes hours to days. Instant approval means no one actually reviewed your case.
Red flag 2: No state license verification. The platform doesn't disclose which states it operates in, or doesn't verify your state of residence. Prescribing across state lines without proper licensing is illegal.
Red flag 3: Prescriptions without patient-specific dosing. The platform offers only one dose option (e.g., "everyone starts at 0.5 mg semaglutide") without titration flexibility. Legitimate prescribing individualizes dose based on tolerance and response.
Red flag 4: No contraindication screening. The intake form doesn't ask about pregnancy, thyroid cancer history, pancreatitis, or other contraindications. Platforms that skip this screening are prioritizing sales over safety.
Red flag 5: Pharmacy location unclear. The platform doesn't disclose which pharmacy will fill your prescription, or the pharmacy is located outside the U.S. Compounded medications must be prepared by U.S.-licensed pharmacies.
Red flag 6: Equivalency claims. The platform claims its compounded product is "the same as Ozempic" or "identical to Wegovy." Compounded medications are not FDA-approved and cannot legally be marketed as equivalent to brand-name drugs.
If you encounter any of these red flags, choose a different platform. The convenience of online prescribing isn't worth the risk of non-compliant or unsafe medication.
The Three-Gate Telehealth Safety Model
FormBlends uses a proprietary three-gate evaluation framework to ensure every prescription meets clinical and legal standards. We're naming it here because it's a reusable model that patients can apply when evaluating any telehealth platform.
Gate 1: Eligibility screening (automated). The intake form includes hard-stop questions that automatically disqualify applicants with absolute contraindications (pregnancy, MTC history, age under 18). This gate prevents contraindicated patients from reaching provider review.
Gate 2: Clinical appropriateness review (provider). A licensed provider reviews the full intake, verifies BMI calculation, evaluates relative contraindications, and makes a clinical judgment about whether GLP-1 therapy is appropriate. This is where the 22% denial rate occurs.
Gate 3: Prescription verification (pharmacy). The compounding pharmacy conducts an independent review of the prescription for accuracy, drug interactions, and dose appropriateness before compounding. The pharmacy can (and does) contact the provider with questions or concerns.
[Diagram suggestion: three-gate flowchart showing patient intake flowing through Gate 1 (automated screening), Gate 2 (provider review), and Gate 3 (pharmacy verification), with rejection paths at each gate leading to "not approved" and approval path leading to "medication shipped"]
The model ensures that three independent checkpoints (platform, provider, pharmacy) review every prescription before medication reaches the patient. Single-gate models (provider review only, no automated screening or pharmacy verification) have higher error rates.
Patients evaluating telehealth platforms should ask: "How many independent reviews does my prescription go through before the medication ships?" If the answer is one, the platform is cutting corners.
FAQ
Can I get a peptide prescription online without a video call? Yes, in 44 states plus D.C. Asynchronous telehealth (intake form review without live video) is legally sufficient for GLP-1 peptide prescriptions in most states. Arkansas, Louisiana, Montana, South Dakota, and Texas require synchronous (live) visits for initial prescriptions.
How long does it take to get approved for a peptide prescription online? Provider review typically takes 24 to 72 hours for asynchronous platforms, or occurs during the live call for synchronous platforms. After approval, pharmacy fulfillment and shipping add another 2 to 5 business days. Total time from intake to delivery: 3 to 10 days.
Do I need a referral from my doctor to get an online peptide prescription? No. Telehealth platforms operate independently. You don't need a referral, prior authorization, or involvement from your primary care provider. However, informing your PCP that you're starting GLP-1 therapy is good practice for coordinated care.
Can I use insurance for compounded peptide prescriptions? Rarely. Most insurance plans don't cover compounded medications. The few that do require prior authorization and documentation that FDA-approved alternatives were tried and failed. The authorization process typically takes weeks and negates the convenience of telehealth. Nearly all online peptide prescriptions are cash-pay.
What's the difference between compounded semaglutide and Ozempic? Ozempic is the FDA-approved brand-name semaglutide manufactured by Novo Nordisk. Compounded semaglutide is prepared by a compounding pharmacy using the same active ingredient but without FDA approval. Compounded versions are legal during FDA shortage periods and cost 70% to 85% less, but they haven't undergone the same review process as FDA-approved drugs.
Are online peptide prescriptions legal? Yes, when issued by a provider licensed in your state and filled by a U.S.-based compounding pharmacy. The legal framework is the same as any telehealth prescription. The provider-patient relationship must meet state telemedicine standards, and the pharmacy must comply with compounding regulations.
Can I get tirzepatide prescribed online? Yes. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is available as a compounded medication through the same telehealth process as semaglutide. Tirzepatide prescriptions require the same eligibility screening and provider review.
What if I'm denied for a peptide prescription online? Most platforms provide a reason for denial and guidance on next steps. Common reasons (BMI too low, contraindicated medication) may be addressable with additional documentation or medical clearance. Absolute contraindications (pregnancy, MTC history) cannot be overridden. If denied, consider an in-person evaluation with an obesity medicine specialist.
Do online peptide prescriptions include follow-up care? Reputable platforms include follow-up check-ins at 2 weeks, 4 weeks, and monthly thereafter. These check-ins assess tolerance, side effects, and dose titration readiness. Platforms that provide medication without ongoing monitoring are not following clinical standards.
Can I switch from brand-name to compounded through an online prescription? Yes. If you're currently on Ozempic, Wegovy, Mounjaro, or Zepbound and want to switch to a compounded version, telehealth platforms can issue a new prescription. You'll need to go through the same intake and provider review process. Inform the provider of your current dose so titration can continue appropriately.
What happens if the compounded peptide shortage ends? The FDA allows compounding of drugs on the shortage list. If semaglutide or tirzepatide are removed from the shortage list, compounding pharmacies can no longer prepare those medications (with limited exceptions for patients with documented allergies to inactive ingredients in brand-name versions). Most telehealth platforms have contingency plans to transition patients to FDA-approved products or alternative therapies if the shortage ends.
Are peptide prescriptions online safe? When obtained through compliant platforms with licensed providers and U.S.-based pharmacies, yes. The safety profile of compounded semaglutide and tirzepatide matches the FDA-approved versions because the active ingredient is identical. The risks are the same as any GLP-1 therapy (nausea, gastroparesis, potential thyroid effects), not unique to compounded or online-prescribed versions. The key is ensuring the platform follows proper screening and prescribing standards.
Sources
- American Telemedicine Association. State Telemedicine Policy Trends, 2024-2026. Journal of Telemedicine and Telecare. 2026.
- Federation of State Medical Boards. Telemedicine Policies by State. FSMB Interstate Medical Licensure Compact. 2025.
- National Association of Boards of Pharmacy. Compounding Pharmacy Compliance Survey. NABP Foundation. 2025.
- American Association of Nurse Practitioners. APRN Prescribing Authority and Telehealth Utilization. AANP Policy Brief. 2025.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA Guidance Documents. 2024.
- Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps, Telehealth Utilization Data. CDC BRFSS. 2025.
- Ryan Haight Online Pharmacy Consumer Protection Act. 21 U.S.C. § 841. 2008.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- American Society of Health-System Pharmacists. Drug Shortages Statistics and Compounding Impact Analysis. ASHP Shortage Database. 2026.
- National Institutes of Health. GLP-1 Receptor Agonists: Mechanism and Clinical Applications. NIH MedlinePlus. 2024.
- U.S. Pharmacopeia. Compounding Quality Standards, USP General Chapters 795, 797, 800. USP Compounding Compendium. 2025.
- Garvey WT et al. American Association of Clinical Endocrinologists Guidelines for Obesity Management. Endocrine Practice. 2023.
- National Conference of State Legislatures. Telehealth Policy Trends: Prescribing Standards Across States. NCSL Health Program. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →